$BGXX
Bright Green Corp Stock $bgxx

$bgxx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014864 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.380M	$1.320M	$8.253M
YoY Change	-51.2%	-9.07%	-68.98%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$144.0K	$160.9K	$638.5K
YoY Change	-9.54%	-9.58%	-9.39%
% of Gross Profit
Operating Expenses	$1.524M	$1.481M	$8.891M
YoY Change	-48.97%	-9.13%	-67.45%
Operating Profit	-$1.524M		-$8.891M
YoY Change	-48.97%		-67.45%
Interest Expense	$120.00	-$260.00	-$1.630K
YoY Change	-116.67%	-99.88%	-99.23%
% of Operating Profit
Other Income/Expense, Net	$80.12K	-$4.016M	-$4.016M
YoY Change	10966.3%		-1985.44%
Pretax Income	-$1.444M	-$5.497M	-$12.91M
YoY Change	-51.67%	198.35%	-53.1%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.444M	-$5.531M	-$13.13M
YoY Change	-51.75%	179.68%	-52.54%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.07
Diluted Earnings Per Share	-$0.01	-$0.03	-$0.07
COMMON SHARES
Basic Shares Outstanding	190.2M shares	183.9M shares	178.6M shares
Diluted Shares Outstanding	190.2M shares		178.6M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.83K	$10.06K	$10.06K
YoY Change	-81.71%	-97.57%	-97.57%
Cash & Equivalents	$92.83K	$10.06K
Short-Term Investments
Other Short-Term Assets	$42.05K	$258.2K	$258.2K
YoY Change	-76.91%	231.7%	231.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$134.9K	$268.3K	$268.3K
YoY Change	-80.44%	-45.52%	-45.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.84M	$16.41M	$16.41M
YoY Change	-17.08%	-4.31%	-4.31%
Goodwill
YoY Change
Intangibles	$9.010K	$1.000K
YoY Change	801.0%	0.0%
Long-Term Investments	$0.00	$726.3K	$726.3K
YoY Change	-100.0%	437.41%	-81.8%
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$15.85M	$17.13M	$17.13M
YoY Change	-34.51%	-23.15%	-23.15%
TOTAL ASSETS
Total Short-Term Assets	$134.9K	$268.3K	$268.3K
Total Long-Term Assets	$15.85M	$17.13M	$17.13M
Total Assets	$15.98M	$17.40M	$17.40M
YoY Change	-35.78%	-23.63%	-23.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.769M	$4.175M	$4.175M
YoY Change	-11.83%	-17.06%	-17.06%
Accrued Expenses	$37.22K	$411.1K	$411.1K
YoY Change	-96.07%	-8.1%	-8.1%
Deferred Revenue
YoY Change
Short-Term Debt	$512.7K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.119M	$6.236M	$6.236M
YoY Change	-23.56%	-17.11%	-17.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$201.8K	$201.8K
YoY Change	-100.0%	-94.53%	-94.53%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$201.8K	$201.8K
YoY Change	-100.0%	-94.53%	-94.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.119M	$6.236M	$6.236M
Total Long-Term Liabilities	$0.00	$201.8K	$201.8K
Total Liabilities	$6.119M	$6.438M	$6.438M
YoY Change	-47.1%	-42.57%	-42.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.60M	-$47.20M
YoY Change	24.99%	38.52%
Common Stock	$59.46M	$58.17M
YoY Change	12.18%	27.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.863M	$10.96M	$10.96M
YoY Change
Total Liabilities & Shareholders Equity	$15.98M	$17.40M	$17.40M
YoY Change	-35.78%	-23.63%	-23.63%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.444M	-$5.531M	-$13.13M
YoY Change	-51.75%	179.68%	-52.54%
Depreciation, Depletion And Amortization	$144.0K	$160.9K	$638.5K
YoY Change	-9.54%	-9.58%	-9.39%
Cash From Operating Activities	-$791.8K	$17.83K	-$2.456M
YoY Change	-66.34%	-99.14%	8.38%
INVESTING ACTIVITIES
Capital Expenditures	$89.68K	$329.5K	$2.534M
YoY Change	-86.92%	-93.29%	-75.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$89.68K	-$329.5K	-$2.534M
YoY Change	-86.92%	-95.5%	-82.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.185M
YoY Change			37.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	974.3K	200.0K	4.585M
YoY Change	-68.8%	-87.5%	-70.92%
NET CHANGE
Cash From Operating Activities	-791.8K	17.83K	-2.456M
Cash From Investing Activities	-89.68K	-329.5K	-2.534M
Cash From Financing Activities	974.3K	200.0K	4.585M
Net Change In Cash	92.83K	-111.7K	-404.5K
YoY Change	9.29%	-96.94%	-53.4%
FREE CASH FLOW
Cash From Operating Activities	-$791.8K	$17.83K	-$2.456M
Capital Expenditures	$89.68K	$329.5K	$2.534M
Free Cash Flow	-$881.5K	-$311.7K	-$4.989M
YoY Change	-70.98%	-88.98%	-60.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent		usd
CY2022Q4	us-gaap	Other Investment Not Readily Marketable Fair Value OtherInvestmentNotReadilyMarketableFairValue		usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2022	BGXX	Loss On Forfeited Deposit LossOnForfeitedDeposit		usd
CY2022	BGXX	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet		usd
CY2023	BGXX	Change In Fair Value Of Voting Agreement Derivative ChangeInFairValueOfVotingAgreementDerivative		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	BGXX	Change In Fair Value Of Voting Agreement Derivative ChangeInFairValueOfVotingAgreementDerivative		usd
CY2022	BGXX	Loss On Forfeited Deposit LossOnForfeitedDeposit		usd
CY2022	BGXX	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet		usd
CY2023	BGXX	Payments For Acquire Property Deposits PaymentsForAcquirePropertyDeposits		usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	BGXX	Transfer From Due To Related Party To Related Party Loc TransferFromDueToRelatedPartyToRelatedPartyLOC		usd
CY2022	BGXX	Transfer From Deposit On Equipment To Prepaid Expenses And Other Assets TransferFromDepositOnEquipmentToPrepaidExpensesAndOtherAssets		usd
CY2022	BGXX	Related Party Loc In Exchange For Common Stock For Eb5 Program RelatedPartyLocInExchangeForCommonStockForEb5Program		usd
CY2022	BGXX	Related Party Loc In Exchange For Common Stock And Warrants RelatedPartyLocInExchangeForCommonStockAndWarrants		usd
CY2022	BGXX	Adjustment To Construction In Progress For Cancellation Of Agreement AdjustmentToConstructionInProgressForCancellationOfAgreement		usd
CY2023	us-gaap	Transfer Of Investments TransferOfInvestments		usd
CY2023Q4	us-gaap	Time Deposit Liability Above Us Insurance Limit TimeDepositLiabilityAboveUsInsuranceLimit	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41395
CY2023	dei	Entity Registrant Name EntityRegistrantName	BRIGHT GREEN CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-4600841
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1033 George Hanosh Boulevard
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Grants
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NM
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	87020
CY2023	dei	City Area Code CityAreaCode	(833)
CY2023	dei	Local Phone Number LocalPhoneNumber	658-1799
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	75060837	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	190166318	shares
CY2023	dei	Auditor Location AuditorLocation	East Amherst, NY
CY2023	dei	Auditor Name AuditorName	SRCO, C.P.A., Professional Corporation
CY2023	dei	Auditor Firm AuditorFirmId	6722
CY2023Q4	us-gaap	Cash Cash	10059	usd
CY2022Q4	us-gaap	Cash Cash	414574	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	258230	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	77847	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	268289	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	492421	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1157587	usd
CY2023Q4	us-gaap	Other Investment Not Readily Marketable Fair Value OtherInvestmentNotReadilyMarketableFairValue	726343	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	3990960	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16407415	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17146325	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1000	usd
CY2023Q4	us-gaap	Assets Assets	17403047	usd
CY2022Q4	us-gaap	Assets Assets	22788293	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4175220	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5033831	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	411099	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	447325	usd
CY2023Q4	BGXX	Due To Others Current DueToOthersCurrent	1650000	usd
CY2022Q4	BGXX	Due To Others Current DueToOthersCurrent	1650000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6236319	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7523350	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	201783	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3686107	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	201783	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3686107	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6438102	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11209457	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184758818	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184758818	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	173304800	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	173304800	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18476	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	17329	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	58149938	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45637328	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47203469	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34075821	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10964945	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11578836	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17403047	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22788293	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8252873	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26609241	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1625	usd
CY2023	BGXX	Loss On Forfeited Deposit LossOnForfeitedDeposit	-970026	usd
CY2023	BGXX	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	3045954	usd
CY2022	BGXX	Change In Fair Value Of Voting Agreement Derivative ChangeInFairValueOfVotingAgreementDerivative	213000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	4017605	usd
CY2022	us-gaap	Other Expenses OtherExpenses	213000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12908985	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27526922	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12908985	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-27526922	usd
CY2023	BGXX	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest Equity In Net Losses Of Affiliate IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate	-218663	usd
CY2022	BGXX	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest Equity In Net Losses Of Affiliate IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate	-135155	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13127648	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27662077	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	178574014	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	178574014	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	162058082	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	162058082	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8220399	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3050000	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	863267	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9136733	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18851232	usd
CY2022	BGXX	Stock Cancelled During Period Value Issued For Services StockCancelledDuringPeriodValueIssuedForServices	-17451	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27662077	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11578836	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11578836	usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	395250	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3104750	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3104750	usd
CY2023	BGXX	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	210000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	880000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	10000	usd
CY2023	BGXX	Common Stock And Warrants Issued For Cashless Conversion Of Related Party Line Of Credit CommonStockAndWarrantsIssuedForCashlessConversionOfRelatedPartyLineOfCredit	3609789	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	880000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3234740	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	594478	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13127648	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10964945	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10964945	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13127648	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27662077	usd
CY2022	BGXX	Change In Fair Value Of Voting Agreement Derivative ChangeInFairValueOfVotingAgreementDerivative	213000	usd
CY2023	BGXX	Loss On Forfeited Deposit LossOnForfeitedDeposit	-970026	usd
CY2023	BGXX	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	3045954	usd
CY2023	BGXX	Equity In Net Losses Of Affiliate EquityInNetLossesOfAffiliate	218663	usd
CY2022	BGXX	Equity In Net Losses Of Affiliate EquityInNetLossesOfAffiliate	135155	usd
CY2023	us-gaap	Depreciation Depreciation	638507	usd
CY2022	us-gaap	Depreciation Depreciation	704681	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3829218	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18833781	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	40766	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-90379	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1823389	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4883896	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-36226	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	429298	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	223271	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	106117	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2455612	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2265770	usd
CY2022	BGXX	Payments For Acquire Property Deposits PaymentsForAcquirePropertyDeposits	1157587	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2689115	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2533653	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10522242	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2533653	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14368944	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	400000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5191057	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1611067	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	880000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3050000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3104750	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9136733	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	210000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4584750	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15766723	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-404515	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-867991	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414574	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1282565	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10059	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414574	usd
CY2023	BGXX	Transfer From Due To Related Party To Related Party Loc TransferFromDueToRelatedPartyToRelatedPartyLOC	392194	usd
CY2023	BGXX	Transfer From Deposit On Equipment To Prepaid Expenses And Other Assets TransferFromDepositOnEquipmentToPrepaidExpensesAndOtherAssets	139617	usd
CY2023	BGXX	Related Party Loc In Exchange For Common Stock For Eb5 Program RelatedPartyLocInExchangeForCommonStockForEb5Program	-880000	usd
CY2023	BGXX	Related Party Loc In Exchange For Common Stock And Warrants RelatedPartyLocInExchangeForCommonStockAndWarrants	-3619789	usd
CY2023	BGXX	Adjustment To Construction In Progress For Cancellation Of Agreement AdjustmentToConstructionInProgressForCancellationOfAgreement	-2682000	usd
CY2022	us-gaap	Transfer Of Investments TransferOfInvestments	1650000	usd
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2019-04-16
CY2023	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13127648	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27662077	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2455612	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2265770	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47203469	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34075821	usd
CY2023Q4	BGXX	Working Capital Deficit WorkingCapitalDeficit	5968030	usd
CY2022Q4	BGXX	Working Capital Deficit WorkingCapitalDeficit	7030929	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3104750	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	880000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	210000	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	400000	usd
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	15000000	usd
CY2023	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	392194	usd
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	880000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	22005	shares
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	39.99
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2827960	shares
CY2023Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	14800000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	88690	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	88690	usd
CY2023Q4	us-gaap	Land Land	260000	usd
CY2022Q4	us-gaap	Land Land	260000	usd
CY2023Q4	us-gaap	Investments Investments	726343	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	43867	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	78193	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The amount recognized is the largest amount of tax benefit that is greater than 50% likely to be realized on examination.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zEVwjjARRxh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zA631o2Tb316">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities, and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants, stock options, stock-based compensation, going concern assessment, impairment of non-current assets, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10635866	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Time Deposit Liability Above Us Insurance Limit TimeDepositLiabilityAboveUsInsuranceLimit	187821	usd
CY2022	BGXX	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest Equity In Net Losses Of Affiliate IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate	-135155	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	3990960	usd
CY2023	BGXX	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest Equity In Net Losses Of Affiliate IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterestEquityInNetLossesOfAffiliate	-218663	usd
CY2023Q4	us-gaap	Investments Investments	726343	usd
CY2023	BGXX	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	3045954	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10736269	usd
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8883851	usd
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8883851	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19868407	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19968810	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3460992	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2822485	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16407415	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17146325	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	1000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	1000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1000	usd
CY2022Q4	us-gaap	Construction Contract Cost Progress Payment Offset ConstructionContractCostProgressPaymentOffset	47944	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	392194	usd
CY2023Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	880000	usd
CY2023Q1	us-gaap	Transfer To Investments TransferToInvestments	880000	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	22005	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	39.99
CY2023Q3	us-gaap	Line Of Credit LineOfCredit	3619789	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2827960	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.15
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.13
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2827960	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.00
CY2023Q4	BGXX	Capital Transaction Due To Related Party CapitalTransactionDueToRelatedParty	2090564	usd
CY2023Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
CY2023Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	14800000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184758818	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184758818	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	173304800	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	173304800	shares
CY2023Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	880000	usd
CY2023Q1	us-gaap	Transfer To Investments TransferToInvestments	880000	usd
CY2023Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2827960	shares
CY2023Q3	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	3619789	usd
CY2023Q3	us-gaap	Transfer To Investments TransferToInvestments	3619789	usd
CY2023	BGXX	Warrant Redeemed Or Called During Period Shares WarrantRedeemedOrCalledDuringPeriodShares	200000	shares
CY2022Q3	BGXX	Warrant Redeemed Or Called During Period Value WarrantRedeemedOrCalledDuringPeriodValue	210000	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	800000	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	55617	usd
CY2022Q3	us-gaap	Escrow Deposit EscrowDeposit	7650	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	316850	usd
CY2023Q2	us-gaap	Legal Fees LegalFees	78400	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7399000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6901000	usd
CY2022Q3	BGXX	Decrease In Fair Value Of Warrants DecreaseInFairValueOfWarrants	498000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.3303
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.1390	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0442	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	625000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.385
CY2023Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1800000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.3353
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.3303
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	600000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2425000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.3353
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.3353
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y10M24D
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	625000	shares
CY2022	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	0	shares
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.258	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.258	pure
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13127648	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-27662077	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2520309	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5727839	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-576071	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1309220	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3096380	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7037059	usd
CY2023	BGXX	Valuation Allowances Of Income Tax Expense Benefit ValuationAllowancesOfIncomeTaxExpenseBenefit	-3096380	usd
CY2022	BGXX	Valuation Allowances Of Income Tax Expense Benefit ValuationAllowancesOfIncomeTaxExpenseBenefit	-7037059	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1401963	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	728201	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9716764	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7294146	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11118727	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8022347	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11118727	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8022347	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	201783	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3686107	usd
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_804_eus-gaap--LossContingencyDisclosures_zKb0iAEDdHjl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_821_zSy4PmN6JTwk">Contingencies</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the consolidated balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the consolidated financial statements.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BRIGHT GREEN CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Years Ended December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in United States Dollars)</span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies (continued)</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the <span id="xdx_900_eus-gaap--LossContingencyActionsTakenByDefendant_c20230101__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zL8tvlOr0Wph" title="Contingency, taken by defendant description">Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company.</span> Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The trial date for the case has been scheduled for April 22, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District</i>. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to <span id="xdx_90F_eus-gaap--LossContingencyActionsTakenByDefendant_c20230101__20231231_zrKNWwmYc6Cd" title="Contingency, taken by defendant description">(i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI.</span> The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Loss Contingency Actions Taken By Defendant LossContingencyActionsTakenByDefendant	(i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of BGGI.

Files In Submission

Name	View Source	Status
0001493152-24-014864-index-headers.html	Edgar Link	pending
0001493152-24-014864-index.html	Edgar Link	pending
0001493152-24-014864.txt	Edgar Link	pending
0001493152-24-014864-xbrl.zip	Edgar Link	pending
bgxx-20231231.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
bgxx-20231231_cal.xml	Edgar Link	unprocessable
bgxx-20231231_def.xml	Edgar Link	unprocessable
bgxx-20231231_lab.xml	Edgar Link	unprocessable
bgxx-20231231_pre.xml	Edgar Link	unprocessable
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BGXX
Bright Green Corp Stock $bgxx

2024 Q2 Form 10-K Financial Statement

#000149315224014864 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BGXX Bright Green Corp Stock $bgxx

2024 Q2 Form 10-K Financial Statement

#000149315224014864 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BGXX
Bright Green Corp Stock $bgxx